Tesaro Company Profile (NASDAQ:TSRO)

Analyst Ratings

Consensus Ratings for Tesaro (NASDAQ:TSRO) (?)
Ratings Breakdown: 1 Hold Rating(s), 10 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $79.18 (13.92% downside)

Analysts' Ratings History for Tesaro (NASDAQ:TSRO)
Show:
DateFirmActionRatingPrice TargetActions
7/18/2016Robert W. BairdInitiated CoverageOutperform$105.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/5/2016MizuhoBoost Price TargetBuy$67.00 -> $94.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/1/2016Citigroup Inc.Boost Price TargetBuy$65.00 -> $90.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2016WedbushReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2016FBR & CoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2016Wells Fargo & Co.Reiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2016Leerink SwannBoost Price TargetOutperform$65.00 -> $95.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2016Jefferies GroupDowngradeBuy -> Hold$53.00 -> $75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/14/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/1/2016SunTrust Banks Inc.Initiated CoverageBuy$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/5/2016Lake Street CapitalInitiated CoverageBuy$61.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/31/2015Raymond James Financial Inc.Initiated CoverageStrong-Buy$70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/2/2014GuggenheimInitiated CoverageBuy$46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Tesaro (NASDAQ:TSRO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q1($1.69)($2.22)$2.48 million$0.31 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q4($1.63)($1.89)$3.45 million$0.23 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2015Q315($1.52)($1.66)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($1.14)($1.51)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115($1.12)($1.30)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2015Q414($1.03)($1.33)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014Q314($1.04)($1.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/24/2014Q214($0.87)($1.03)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2014Q114($1.06)($1.43)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2014Q413($0.78)($0.72)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013Q313($0.69)($0.88)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/25/2013Q2 2013($0.63)($0.67)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/25/2013Q1 2013($0.62)($0.66)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/14/2013Q4 2012($0.65)($15.41)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/25/2012($0.55)($0.52)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/26/2012($0.55)($4.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Tesaro (NASDAQ:TSRO)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($1.69)($1.59)($1.64)
Q2 20162($1.69)($1.58)($1.64)
Q3 20163($1.75)($1.49)($1.61)
Q4 20163($1.75)($1.54)($1.61)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Tesaro (NASDAQ:TSRO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Tesaro (NASDAQ:TSRO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/30/2016Jeffrey H HankeVPSell12,500$74.35$929,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2016Edward C EnglishVPSell7,000$40.75$285,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2016Arnold L OronskyDirectorBuy142,085$35.19$4,999,971.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2016Enterprise Associates 13 L NewMajor ShareholderBuy710,429$35.19$24,999,996.51View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2016Edward C EnglishVPSell7,000$43.71$305,970.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2015Edward C. EnglishVPSell17,000$50.19$853,230.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015James O ArmitageDirectorBuy500$54.63$27,315.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2014James O ArmitageDirectorBuy1,000$38.16$38,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2014Lawrence M AllevaDirectorBuy1,100$26.17$28,787.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/31/2013Lawrence M AllevaDirectorBuy1,449$34.33$49,744.17View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2013Peter J BarrisMajor ShareholderSell3,583$39.00$139,737.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/30/2013Lawrence M AllevaDirectorBuy1,050$28.10$29,505.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/1/2012Lawrence M AllevaDirectorBuy3,240$15.45$50,058.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/30/2012Leon O Moulder JrCEOBuy10,000$11.69$116,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Tesaro (NASDAQ:TSRO)
DateHeadline
07/23/16 06:14 PMTESARO Inc. (TSRO) Hits New 52-week High During July 21 Session - Equities.com
07/21/16 03:05 PMTESARO to Announce Second-Quarter 2016 Financial Results on August 4, 2016 - [GlobeNewswire] - WALTHAM, Mass., July 21, 2016-- TESARO, Inc. will announce its second-quarter 2016 financial results on Thursday, August 4, 2016, after the close of the U.S. financial markets. TESARO’ s senior management ...
07/20/16 07:59 PMShares Positive Over the Past Month: Tesaro, Inc. (NASDAQ:TSRO) - TGP
07/20/16 07:59 PMEquity Roundup: Stock Performance Focus on TESARO, Inc. (NASDAQ:TSRO) - Press Telegraph
07/19/16 04:30 AMCoverage initiated on Tesaro by Robert W. Baird -
07/17/16 06:16 PMShare Performance Summary for: Tesaro, Inc. (NASDAQ:TSRO) - Press Telegraph
07/16/16 06:13 PMOracle Investment Management INC Increased Tesaro INC (NASDAQ:TSRO) by $4.40 Million as Shares Declined - Consumer Eagle
07/15/16 05:54 PMShares Experiencing a Downtrend: Tesaro, Inc. (NASDAQ:TSRO) - TGP
07/15/16 05:54 PMBroker Outlook For TESARO, Inc. (NASDAQ:TSRO) - Fiscal Standard
07/13/16 07:16 PMStocks Analysts Ranking Summary: Humana Inc. (NYSE:HUM) , TESARO, Inc. (NASDAQ:TSRO) - Street Updates
07/10/16 06:01 PMNext Weeks Broker Price Targets For TESARO, Inc. (NASDAQ:TSRO) - Fiscal Standard
07/09/16 06:10 PMTESARO (TSRO), ENGOT Announces Positive Data From ENGOT-OV16/NOVA Phase 3 Trial
07/08/16 03:21 PMENGOT and TESARO Partnership Generates Positive Data From ENGOT-OV16/NOVA Phase 3 Trial - [at noodls] - The ENGOT-OV16/NOVA trial successfully achieved its primary endpoint of PFS in the germline BRCA mutant cohort The ENGOT-OV16/NOVA trial successfully achieved its primary endpoint of PFS in the non-germline ...
07/08/16 09:45 AMAnalyst Recommended Stock: Tesaro, Inc. (NASDAQ:TSRO) - News Oracle
07/08/16 09:45 AMTESARO Inc. (TSRO) is Trading Higher on Unusual Volume for July 06 - Equities.com
07/07/16 03:32 PMTESARO, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits -
07/07/16 03:31 PMTESARO Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters - [at noodls] - WALTHAM, Mass., July 07, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) today announced the closing of its previously announced underwritten public offering of common stock. TESARO sold 5,347,500 ...
07/07/16 09:39 AMWill TESARO, Inc. (NASDAQ:TSRO) Surprise Analysts? - Investor Newswire
07/07/16 09:39 AMAnalysts Reviewing Stocks: AbbVie Inc. (NYSE:ABBV) , TESARO, Inc. (NASDAQ:TSRO) - Street Updates
07/06/16 07:23 PMStock in Overbought Territory: Tesaro, Inc. (NASDAQ:TSRO) - Press Telegraph
07/06/16 07:23 PMStock to keep an eye on: Tesaro, Inc. (NASDAQ:TSRO) - News Oracle
07/06/16 07:23 PMSouthwest Airlines Co (NYSE:LUV) & TESARO Inc (NASDAQ:TSRO) Movers to Watch - Money News (press release)
07/06/16 07:23 PMTesaro Inc (TSRO): Is There More Upside for Tesaro Stock? - Investorplace.com
07/05/16 09:54 AMTesaro Inc (TSRO): Is There More Upside for Tesaro Stock? - InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Tesaro (TSRO) has already made a mint for investors thanks to a 50% spike on positive news about its ovarian cancer treatment, niraparib. What's left in the tank? The post Tesaro Inc (TSRO): Is There More Upside for Tesaro Stock? appeared first on InvestorPlace.
07/03/16 07:49 AMShare Performance Recap for: Tesaro, Inc. (NASDAQ:TSRO) - Press Telegraph
07/03/16 06:50 AMA Big Breakthrough for Ovarian Cancer Patients - Tesaro's PARP-inhibitor niraparib just delivered remarkable results when used in previously treated ovarian cancer patients.
07/02/16 09:31 AMTESARO Inc (NASDAQ:TSRO) & McCormick & Company, (NYSE:MKC) Stocks Trending Alert - Money News (press release)
07/02/16 09:31 AMTESARO Inc. (TSRO) Jumps 8.59% on June 30 - Equities.com
07/02/16 09:31 AMTESARO Inc. (TSRO) Hits New 52-week High During June 30 Session - Equities.com
07/02/16 09:31 AMAnalysts Shine Light on Two Volatile Healthcare Stocks: TESARO Inc (TSRO) and Marinus Pharmaceuticals Inc (MRNS) - Smarter Analyst
07/02/16 09:31 AMTESARO Inc. (TSRO) Announces Proposed Public Offering of Common Stock - ValueWalk
07/01/16 09:34 AMTESARO Announces Pricing of Public Offering of Common Stock
07/01/16 09:07 AM​Tesaro raises $377M in largest local biotech stock offering in the past year -
06/30/16 07:04 PMTESARO Skyrockets On Phase-3 Data
06/30/16 05:31 PMTesaro Stock Up on Successful Phase III Ovarian Cancer Trial -
06/30/16 03:59 PMTESARO Commences Public Offering Worth $300 Million - TESARO, Inc. (NASDAQ: TSRO) revealed it started an underwritten public offering of $300 million of its common stock. According to the company, it intends to grant the underwriters an option to acquire a maximum of $45 million ...Full story available on Benzinga.com
06/30/16 10:04 AMBRIEF-Tesaro files for mixed shelf offering - SEC filing - * Says files for mixed shelf offering with the U.S. SEC; size undisclosed - SEC filing Source: (http://1.usa.gov/295fkJh ) Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
06/30/16 09:40 AMTESARO : TESAROs Niraparib Significantly Improved Progression-Free Survival for Patients With Ovarian Cancer in Both Cohorts of the Phase 3 NOVA Trial
06/30/16 09:40 AMTESARO Announces Proposed Public Offering of Common Stock
06/30/16 09:40 AMTesaro's stock drops, as stock offering comes a day after stock doubles
06/30/16 09:40 AMTesaro Inc. (TSRO) Soared To A New High On Phase 3 Study Results
06/30/16 09:40 AMAnalyst Upgrades: General Electric Company, TESARO Inc, and Yelp Inc
06/29/16 06:51 PMTesaro (TSRO) Skyrockets on Phase 3 Ovarian Cancer Data
06/29/16 06:51 PMWhy Tesaro Inc (TSRO), Clovis Oncology Inc (CLVS) and Twilio Inc (TWLO) Are 3 of Today’s Best Stocks
06/29/16 06:34 PMTesaro cancer drug trial success -
06/29/16 04:19 PMWhy Under Armour, Tesaro, and Diamond Resorts International Jumped Today -
06/29/16 12:40 PMShares of Tesaro, Inc. Have More Than Doubled Today. Here's Why - The company reported great-looking data from a pivotal phase 3 trial, causing shares to skyrocket.
06/29/16 09:39 AMTESARO’s Niraparib Significantly Improved Progression-Free Survival for Patients With Ovarian Cancer in Both Cohorts of the Phase 3 NOVA Trial
06/29/16 09:39 AMBuzz Stocks: TESARO Inc, Lipocine Inc, and Energy Transfer Equity LP
06/29/16 09:39 AMTESARO (TSRO) Phase 3 NOVA Trial of Niraparib Achieves Primary Endpoint

Social

About Tesaro

Tesaro logoTESARO, Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio, Inc., for the discovery and development of antibodies for several specified immuno-oncology targets.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: TSRO
  • CUSIP: 88156910
Key Metrics:
  • Previous Close: $91.99
  • 50 Day Moving Average: $64.24
  • 200 Day Moving Average: $47.33
  • P/E Ratio: N/A
  • P/E Growth: 3.87
  • Market Cap: $4.22B
  • Beta: 1.62
  • Current Year EPS Consensus Estimate: $-7.19 EPS
  • Next Year EPS Consensus Estimate: $-5.07 EPS
Additional Links:
Tesaro (NASDAQ:TSRO) Chart for Sunday, July, 24, 2016